ESTRELLA IMMUNOPHARMA, INC. (ESLA) scores 0 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.
View full ESLA analysis on boothcheck